A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients To investigate the pharmacodynamics (PD) of BIM 23A760, administered by single subcutaneous (s.c.) injection to acromegalic patients.

• Country None
• organs None
• Specialty None

PHASE III, MULTICENTRE, OPEN STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILES OF THE CO-ADMINISTRATION OF LANREOTIDE AUTOGEL 120 MG (ADMINISTERED VIA DEEP SUBCUTANEOUS INJECTIONS EVERY 28 DAYS) AND PEGVISOMANT 40 TO 120 MG PER WEEK (ADMINISTERED VIA SUBCUTANEOUS ROUTE ONCE OR TWICE A WEEK) IN ACROMEGALIC PATIENTS FAILING TO RESPOND TO LANREOTIDE AUTOGEL 120 MG ALONE To assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via su...

• Country None
• organs None
• Specialty None

A Phase IV, Randomised, Double-blind, Dose-ranging, Study in Children and Young People to determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spasticity due to Cerebral Palsy To compare the effectiveness of 3 doses of Dysport (5, 10 or 15 Units/Kg/painful hip) in the management of chronic hip pain due to cerebral palsy in children/young people. The primary endpoint will b...

• Country None
• organs None
• Specialty None

Étude MM-398-07-02-03 : étude de phase 2 randomisée visant à comparer la sécurité, la tolérance et l’efficacité de l’irinotécan nanoliposomal (nal-IRI) en association à d’autres traitements anticancéreux au nab-paclitaxel associé à la gemcitabine chez des patients ayant un adénocarcinome du pancréas métastatique non traité antérieurement. [essai clos aux inclusions] Le cancer du pancréas prend naissance dans les cellules du pancréas, le plus souvent dans les cellules du canal pancréatique, donnant lieu à l’adénocarcinome du pancréas, qui représente 95 % des cas d...

• Country France
• organs Pancréas
• Specialty Chimiothérapie

Patient satisfaction in the treatment of anal fissure Not provided at time of registration

• Country None
• organs None
• Specialty None

PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACROMEGALIC PATIENTS Part A: To assess the efficacy of repeated s.c. injections at different doses of BIM 23A760 on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in acromegalic patients after 6 month...

• Country None
• organs None
• Specialty None

Phase IIIB, international, single group, open study to define an optimal monitor-ing of IGF-I in children treated with NutropinAq™, using a novel capillary blood collection method The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients.

• Country None
• organs None
• Specialty None

Étude D-FR-01072-001 : étude de phase 1-2 évaluant la sécurité, la tolérance et l’efficacité du 177lu-OPS201 chez des patients ayant des tumeurs neuroendocrines positives aux récepteurs de la somatostatine. [essai clos aux inclusions] Les cellules neuroendocrines sont dispersées dans tout le corps. On les trouve dans la plupart des organes du corps, y compris dans le tube digestif, le pancréas, la thyroïde et les poumons. Elles reç...

• Country France
• organs Système endocrinien - autres, Système nerveux - autres
• Specialty Radiothérapie

Phase 3, blinded, multicentre study assessing efficacy and safety of Dysport for treatment of upper limb spasticity (altered skeletal muscle performance) in children The primary study objective is to assess the efficacy of two doses of Dysport (8 U/kg and 16 U/kg) compared to Dysport 2 U/kg used in the treatment of upper limb spasticity in children with CP followi...

• Country None
• organs None
• Specialty None

A clinical trial to determine the maximum dose, safety and tolerability of one injection of lanreotide prolonged release formulation in patients with acromegaly previously treated with either octreotide LAR or lanreotide Autogel To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegaly

• Country None
• organs None
• Specialty None